alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 201–225 of 788 studies published 2014 (page 9 of 32) · 27,380 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Mortality risk after dementia diagnosis by dementia type and underlying factors: a cohort of 15,209 patients based on the Swedish Dementia Registry

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Journal of Alzheimer's disease : JAD 2014-01-01

Knowledge on survival in dementia is crucial for patients and public health planning. 4 key findings →

Participants: 15,209 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Development and validation of a brief dementia screening indicator for primary care

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2014-02-01

The final Dementia Screening Indicator included age (1 point/year; ages, 65-79 years), less than 12 years of education (9 points), stroke (6 points), diabetes mellitus (3 points), body mass index less than 18.5 kg/m(2) (8 points), requiring assistance with money or medications (10 points), and depressive symptoms (6 points). 4 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Association of brain amyloid-β with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Brain : a journal of neurology 2014-03-12

Patients with Alzheimer's disease have reduced cerebral blood flow measured by arterial spin labelling magnetic resonance imaging, but it is unclear how this is related to amyloid-β pathology. 4 key findings →

Participants: 51 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Comprehensive Longitudinal Health Care in the Home for High‐Cost Beneficiaries: A Critical Strategy for Population Health Management

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Journal of the American Geriatrics Society 2014-10-01

Despite using more home health and hospital services than controls in the baseline preenrollment period, which suggests that they were sicker, participants receiving house calls had 17% lower overall Medicare costs than controls, and there was no indication of poorer quality of care, greater mortality, or underservice. 4 key findings →

Design: prospective cohort Participants: 9,425 Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

End-of-life care in general practice: A cross-sectional, retrospective survey of 'cancer', 'organ failure' and 'old-age/dementia' patients

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Palliative medicine 2014-03-18

The results highlight the need to integrate palliative care with optimal disease management in primary practice and to initiate advance care planning early in the chronic disease trajectory to enable all patients to live as well as possible with progressive illness and die with dignity and comfort. 2 key findings →

Design: cross-sectional Participants: 1,491 Evidence: low

Full summary, score breakdown and related studies → Original source

Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Journal of Alzheimer's disease : JAD 2014-01-01

Cholinesterase inhibitors and memantine are able to stabilize or slow decline in cognition, function, behavior, and global change. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Multiple anticholinergic medication use and risk of hospital admission for confusion or dementia

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Journal of the American Geriatrics Society 2014-10-03

Taking more anticholinergic medications is associated with greater risk of hospitalization for confusion or dementia. 3 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source

Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Neurology 2014-04-04

We describe a 2-feature biomarker approach to classifying elderly CN subjects that is complementary to the National Institute on Aging-Alzheimer's Association preclinical staging criteria. 2 key findings →

Participants: 252 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers

✓ Peer-reviewed alzhub usefulness score 56 out of 100. JAMA neurology 2014-07-01

Microbleed presence was associated with lower CSF Aβ42 in AD and vascular dementia (standardized beta = -0.09, P = .003; standardized beta = -0.30, P = .01), and higher CSF tau in controls (standardized beta = 0.10, P = .03). 4 key findings →

Design: cross-sectional Participants: 914 Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Effects of galantamine and galantamine combined with nimodipine on cognitive speed and quality of life in mixed dementia: a 24-week, randomized, placebo-controlled exploratory trial (the REMIX study)

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Arquivos de neuro-psiquiatria 2014-06-01

Twenty-one patients received at least one drug dose (9 GAL/NIM and 12 GAL/PLA). 3 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Anatomical heterogeneity of Alzheimer disease: based on cortical thickness on MRIs

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Neurology 2014-10-24

This cluster analysis of cortical thickness of the entire brain showed that AD dementia in the earlier stages can be categorized into various anatomical subtypes, with distinct clinical features. 5 key findings →

Participants: 52 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cerebrospinal fluid β-amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Annals of neurology 2014-06-13

Our data suggest that interactions between biomarkers in AD result in a 2-phase phenomenon of pathological cortical thickening associated with low CSF Aβ, followed by atrophy once CSF p-tau becomes abnormal. 3 key findings →

Design: cross-sectional Participants: 145 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

The overlap between vascular disease and Alzheimer's disease--lessons from pathology

✓ Peer-reviewed alzhub usefulness score 56 out of 100. BMC medicine 2014-11-11

Recent epidemiological and clinico-pathological data indicate considerable overlap between cerebrovascular disease (CVD) and Alzheimer's disease (AD) and suggest additive or synergistic effects of both pathologies on cognitive decline. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Subjective cognitive concerns and neuropsychiatric predictors of progression to the early clinical stages of Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 56 out of 100. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2014-02-26

From a total sample of 559 older adults from the Massachusetts Alzheimer's Disease Research Center longitudinal cohort, 454 were included in the primary analysis: 283 with clinically normal cognition (CN), 115 with mild cognitive impairment (MCI), and 56 with subjective cognitive concerns (SCC) but no objective impairment, a proposed transitional group between CN and MCI. 1 key finding →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed